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Th17 Cytokines Stimulate CCL20 Expression in
Keratinocytes In Vitro and In Vivo: Implications for
Psoriasis Pathogenesis
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David Purdy3, Erin Fitch1,4, Mihail Iordanov3 and Andrew Blauvelt1,2,4
T helper (Th) 17 cells have recently been implicated in psoriasis pathogenesis, but mechanisms of how these
cells traffic into inflamed skin are unknown. By immunostaining for interleukin (IL)-17A and IL-22, we show
numerous cells present in psoriasis lesions that produce these cytokines. We next found that Th17 cytokines (IL-
17A, IL-22, and tumor necrosis factor (TNF)-a) markedly increased the expression of CC chemokine ligand (CCL)
20, a CC chemokine receptor (CCR)6 ligand, in human keratinocyte monolayer and raft cultures in a dose- and
time-dependent manner. Lastly, we showed in mice that subcutaneous injection with recombinant IL-17A, IL-22,
or TNF-a led to the upregulation of both CCL20 and CCR6 expression in skin as well as cutaneous T-cell
infiltration. Taken together, these data show that Th17 cytokines stimulate CCL20 production in vitro and in vivo,
and thus provide a potential explanation of how CCR6-positive Th17 cells maintain their continual presence in
psoriasis through a positive chemotactic feedback loop.
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INTRODUCTION
Interleukin (IL)-23 is a heterodimeric protein consisting of
p19 and p40 subunits that is overexpressed in psoriasis
lesional skin, as shown by increased p19 and p40 transcripts
(Lee et al., 2004; Chan et al., 2006; Zaba et al., 2007) and by
the presence of elevated numbers of p19-positive and p40-
positive dendritic cells detected by immunohistochemistry
(IHC) in the dermis of the affected skin (Lee et al., 2004;
Piskin et al., 2006; Wilson et al., 2007). IL-23 is also
expressed by keratinocytes (KC) in lesional psoriatic skin
(Piskin et al., 2006), although transcripts and protein appear
less abundant when compared with dendritic cells. By
contrast, most recent reports show no increased expression
of the IL-23-related protein, IL-12, in psoriasis; that is,
transcripts for the IL-12-specific subunit p35 are not increased
in psoriatic plaques (Lee et al., 2004; Chan et al., 2006; Zaba
et al., 2007). Furthermore, large-scale genomic studies have
identified IL-23R, specific for IL-23 signaling, as a psoriasis
susceptibility gene, whereas no psoriasis association was
found for IL-12Rb1, the signaling receptor for IL-12 (Capon
et al., 2007; Cargill et al., 2007).
IL-23 promotes survival and proliferation of T helper (Th)
17 cells, whereas IL-12 promotes the development of Th1
cells (Blauvelt, 2007; Fitch et al., 2007). In psoriasis, a large
body of literature supports the presence of interferon (IFN)-g
in psoriasis (Austin et al., 1999; Zhou et al., 2003; Lew et al.,
2004), which has long been regarded as a prototypic Th1
cell-derived cytokine. Of recent relevance, a distinct subset
of human Th17 cells have also been shown to produce IFN-g
(Annunziato et al., 2007; Acosta-Rodriguez et al., 2007a, b;
Wilson et al., 2007), so that the presence of IFN-g and
downstream IFN-g-regulated genes in psoriasis, as well as
other human diseases, can no longer be equated with the
presence of Th1 cells and with a ‘‘Th1 disease’’ state.
Recently, transcripts for Th17 cell-specific cytokines, notably
IL-17A and IL-22, have been documented at high levels in
psoriasis (Chan et al., 2006; Wolk et al., 2006; Wilson et al.,
2007; Zaba et al., 2007) and Th17 cells have been identified
by flow cytometry in lesions of psoriasis (Lowes et al., 2008).
Quantification of Th17 cytokine-producing cells within
psoriatic tissue by IHC has not been published to date.
Little is known about how Th17 cells traffic into skin.
Recently, several groups have characterized the chemokine
receptor expression pattern on human Th17 cells, and found
that Th17 cells, secreting IL-17A, but not IFN-g, express CC
chemokine receptors (CCR) 6 and CCR4, whereas CCR6 and
CXC chemokine receptor 3 positivity identified both Th17 T
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cells that secreted both IL-17A and IFN-g and Th1 cells that
secrete IFN-g (Annunziato et al., 2007; Acosta-Rodriguez
et al., 2007a, b). Consistently, differentiation of T cells into a
Th17 phenotype resulted in a preferential induction of CCR6
expression and CCR6 was expressed on all IL-17-producing
cells (Singh et al., 2008). A recent report by Hirota et al.
(2007) confirmed that Th17 T cells predominantly express
CCR6, whereas Th1 cells do not. This group also reported
that CCR6 was critical for leukocyte migration into inflamed
joints in a mouse model rheumatoid arthritis (Hirota et al.,
2007). By contrast, Lim et al. (2008) reported that Th17, Th1,
Th2, and regulatory T cells exhibit significant overlap in
chemokine receptor expression patterns and this overlap
allows for co-migration of different T-cell subsets to the site of
tissue inflammation.
The primary chemokine ligands for CCR6, CC chemokine
ligand (CCL) 20 and b-defensin 2, are upregulated in
psoriasis (Homey et al., 2000; Ong et al., 2002;
Wilson et al., 2007). In skin, these two chemotactic
molecules are produced predominantly by KC and CCL20
is a key stimulus for chemoattracting both CCR6-positive
immature dendritic cells (Le Borgne et al., 2006) and T cells
(Varona et al., 2005; Paradis et al., 2007) from blood into
inflamed cutaneous tissue. Currently, little is known about
whether Th17 cytokines affect CCL20 production in KC. In
this report, we found that IL-17A, IL-22, and tumor necrosis
factor (TNF)-a stimulated CCL20 expression by KC. These
results suggest a mechanism by which Th17 cells can
promote their continued presence in psoriatic tissue, by
stimulating a positive chemotactic feedback loop that
involves KC-derived CCL20 and CCR6 expressed on Th17
cell surfaces.
RESULTS AND DISCUSSION
IL-17A-positive and IL-22-positive cells are present in psoriasis
lesional skin
Transcript levels for IL-17A and IL-22 are increased in
psoriasis plaques (Chan et al., 2006; Wolk et al., 2006;
Wilson et al., 2007; Zaba et al., 2007), however, quantifica-
tion of Th17 cells within lesions of psoriasis by IHC had not
been previously published. We found abundant IL-17A-
positive cells (Figure 1, Table 1) and many (although fewer)
IL-22-positive cells (Figure 1, Table 2) in skin affected by
psoriasis. We determined optimal IHC staining conditions for
these cytokines using formalin-fixed (for IL-17A IHC) and
fresh-frozen (for IL-22 IHC) tissue sections (data not shown).
In these experiments, IL-17A-positive cells were more
numerous than IL-22-positive cells, although this could
simply be a feature of differing antibody affinities for each
of these cytokines. By comparison, CD3 positive T cells were
on average 2.4 times more abundant than IL-17A-positive
cells and 5.7 times more abundant than IL-22-positive cells
(Tables 1 and 2). Single IL-17A-positive or IL-22-positive
immunoreactive cells were present throughout the dermal
papillae and upper dermis. No positive cells were found in
more superficial regions of the epidermis. The cells were
small and mostly round, consistent with the morphology of T
cells. Only rare IL-17A- or IL-22-positive cells were detected
in tissue sections obtained from normal skin of healthy
individuals (Figure 1).
The demonstration of numerous IL-17A-positive cells and
less abundant IL-22-positive cells localizing to psoriasis
lesions is consistent with the high levels of transcripts for
these Th17 cytokines detected by previous RT-PCR studies
(Chan et al., 2006; Wolk et al., 2006; Wilson et al., 2007;
Zaba et al., 2007). These data are also consistent with recent
flow cytometry studies on T-cell populations isolated from
psoriatic skin explants, where IL-17Aþ T cells were
identified in less than 10% of T cells (Kryczek et al., 2008;
Lowes et al., 2008). Because of the time tissue manipulation
and ex vivo culture conditions required to quantify IL-17Aþ
cells in psoriatic lesions by flow cytometry, we believe these
methods would be predicted to underestimate the actual
number of IL-17Aþ cells in psoriatic tissue when compared
with IHC. We doubt that our IL-17A staining is due to
extracellular-bound IL-17A, as keratinocytes express IL-17
receptors, and these cells did not stain positively in our
experiments (Figure 1). A limitation of our study, however, is
that we cannot definitively conclude that our IL-17Aþ and
IL-22þ cells represent Th17 cells. It will be important to
perform IHC double-labeling experiments on psoriatic tissue
to identify these cells as Th17 cells.
IL-17A, IL-22, and TNF-a increase CCL20 mRNA and protein
expression by normal human KC in vitro
Using normal human KC cultured as monolayers on plastic
dishes, we found that IL-17A, IL-22, and TNF-a markedly
upregulated CCL20 mRNA at 24 hours in a dose-dependent
manner (Figure 2a–c). Optimal cytokine stimulation dosage
was found to be 100 ngml1 for both IL-17A and TNF-a (19-
and 45-fold increases, respectively, normalized to GAPDH
expression and compared with no cytokine stimulation),
whereas 10 ngml1 was optimal for IL-22 (17-fold increase)
(Figure 2a–c). In contrast, neither TGF-b1 nor IFN-g increased
CCL20 expression by KC (data not shown). Using these
optimal doses, we also found Th17 cytokines upregulate
CCL20 mRNA expression in a time-dependent manner
(Figure 2d–f). The various cytokines each had somewhat
different time course patterns, with IL-17A and IL-22 showing
maximal CCL20 mRNA expression at 24 hours post treat-
ment, and TNF-a at 48 hours. Dose- and time-dependent
increases in CCL20 protein were also demonstrated by ELISA
using cell-free supernatants of KC cultures under the same
cytokine-stimulated conditions described above (Figure 3a–f).
IL-17A, IL-22, and TNF-a increase CCL20 mRNA and protein
expression by reconstructed human epidermis (RHE)
KC grown as monolayers on plastic dishes differentially
respond to certain cytokine signals when compared with KC
grown on dermal substrates at air–liquid interfaces, which
allows for KC stratification and terminal differentiation
(Poumay et al., 2004; Farley et al., 2006, 2008). These KC
cultures are called as reconstructed human epidermis (RHE)
because they resemble normal human epidermis, and may be
a more physiologic model for studying KC biology when
compared with KC grown in monolayers on plastic. To study
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Figure 1. IL-17A-positive and IL-22-positive cells are abundant in psoriasis lesional skin. Formalin-fixed paraffin-embedded tissue sections obtained from seven
psoriasis patients and three healthy individuals were examined by IHC. Tissue was stained with either anti-CD3 or anti-IL-17A antibodies. In six separate
individuals with psoriasis, lesional skin was biopsied and snap frozen. Fresh-frozen sections were stained with either anti-CD3 or anti-IL-22 antibodies.
Increased numbers of IL-17A- and IL-22-expressing cells (brown or purple in color) were present in lesional skin when compared with healthy skin.
Representative photos are shown. Bar¼10 mm in figures labeled  40, 20 mm in figures labeled  20, and 40 mm in figures labeled 10.
Table 1. IL-17A-positive cells are abundant in
formalin-fixed psoriasis tissue
CASE No.
CD3 positive
(cells per HPF
in 10h.p.f.)
IL-17A positive
(cells per HPF
in 10h.p.f.)
CD3 positive/
IL-17A positive
1 39.6 15.5 2.6
2 43.8 24.9 1.8
3 79.3 29.4 2.7
4 89.9 43.6 2.1
5 99 49.8 2.0
6 86.1 27.2 3.2
7 103.6 43.3 2.4
Mean 77.3 33.4 2.4
HPF, high-power field.
Table 2. IL-22-positive cells are present in fresh-
frozen lesional psoriasis tissue
CASE
No.
CD3 positive
(cells per HPF in
10 h.p.f.)
IL-22 positive
(cells per HPF
in 10 h.p.f.)
CD3 positive/
IL-22 positive
8 31.8 5.5 5.8
9 47.3 11.7 4.0
10 29.6 6.5 4.6
11 69.8 11.1 6.3
12 95.1 11.7 8.1
13 44.3 8.3 5.3
Mean 53.0 9.1 5.7
HPF, high-power field.
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CCL20 mRNA and protein expression following stimulation
with Th17 cytokines using this model, RHE were treated with
10 or 100 ngml1 of IL-17A, IL-22, or TNF-a for either 6 or
24 hours. IL-17A, IL-22, and TNF-a stimulated CCL20 mRNA
and protein production in a dose- and time-dependent
manner (Figure 4a–f).
In both monolayers of KC and RHE, Th17 cytokines
induced the expression of CCL20 mRNA and protein (Figures
2–4). In order of potency, all of the in vitro KC experiments
suggest that TNF-a is the most potent Th17 cytokine that
induces CCL20 expression, with IL-17A showing the next
highest effects followed by IL-22. It is interesting to speculate
that TNF-a-blocking agents for psoriasis may work at least in
part by blocking TNF-a-induced upregulation of CCL20.
These findings are consistent with previous reports indicating
that IL-17A induces CCL20 expression by KC (Homey et al.,
2000), airway epithelial cells (Kao et al., 2005), and
synoviocytes (Hirota et al., 2007). In addition, Kao et al.
(2004) reported that IL-17A stimulated b-defensin 2, another
CCR6 ligand, in airway epithelium. Importantly, we extend
the KC results of (Homey et al., (2000) by (1) showing that
additional Th17 cytokines can stimulate CCL20 production
(Figures 2–4), by (2) reporting that RHE, in addition to
monolayers of KC, can be stimulated by Th17 cytokines to
produce CCL20 (Figure 4), and by (3) showing that injection
of these cytokines induces the upregulation of CCL20 and
CCR6 as well as T-cell infiltration in vivo (see Figure 5
below).
CCL20 and CCR6 upregulation and T-cell infiltration in murine
skin injected with Th17 cytokines
Ears of Balb/c mice were injected with 500 ng of recombinant
murine IL-17A, IL-22, TNF-a, or PBS daily for 5 days. Total
RNA or total protein were extracted from each ear and CCL20
and CCR6 mRNA expression was assessed by real-time
RT-PCR, whereas CCL20 protein expression was assessed by
ELISA. CCL20 mRNA was markedly upregulated by all of the
Th17 cytokines, with TNF-a causing the greatest increase
(mean of 55-fold compared with PBS-injected ears), and IL-
17A and IL-22 causing 3-fold and 2.5-fold elevations,
respectively (Figure 5a). Both TNF-a and IL-17A injections
led to concomitant increases in CCL20 protein levels in
cytokine-injected ears (Figure 5b), whereas IL-22-injected
ears showed no clear elevations in CCL20 protein expression
in these experiments. Similarly, CCR6mRNA was elevated by
TNF-a, IL-17A, and IL-22 by 4-, 2-, and 2.5-fold, respectively,
when compared with PBS-injected ears (Figure 5c). Lastly, we
showed that Th17 cytokine injections induced CD3-positive
T-cell infiltration within murine skin (Figure 5d). Only rare T
cells were observed in PBS-injected skin (Figure 5d).
CCR6–CCL20 interactions have been studied in the
context of dendritic cell and T-cell trafficking in other murine
diseases. Specifically, immature CCR6-positive dendritic
cells were recruited to sites of inflamed epithelial tissue in
mice following trauma (Le Borgne et al., 2006). CCR6 was
also shown to be critical in T-cell trafficking into skin in
murine models of graft-versus-host disease (Varona et al.,
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Figure 2. IL-17A, IL-22, and TNF-a increase CCL20 mRNA expression by normal human KC in a dose- and time-dependent manner in vitro. Cells were treated
with the indicated concentrations of (a) IL-17A, (b) IL-22, or (c) TNF-a for 24 hours. Cells were treated with the optimal cytokine concentrations of (d) IL-17A, (e)
IL-22, or (f) TNF-a for 6, 24, or 48 hours. mRNA was harvested and CCL20 transcripts were quantified by real-time RT-PCR analyses for all experiments. All
experiments were performed in triplicate at least three separate times and the average mRNA increase and SD is reported. Significant differences were detected
using the Mann–Whitney unpaired two-tailed t-test (*Indicates significance, Po0.05).
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2005) and contact hypersensitivity (Paradis et al., 2007).
Recently, CCR6–CCL20 interactions were shown to be
critical in mediating leukocyte migration into inflamed joints
in a mouse model of rheumatoid arthritis; anti-CCR6
monoclonal antibodies inhibited Th17 T-cell trafficking and
early disease development in this model (Hirota et al., 2007).
In short-term 5-day experiments, we show for the first time
that Th17 cytokines induce CCL20 and CCR6 in vivo, with
influx of T cells into skin. It is noteworthy that we did not
observe keratinocyte hyperproliferation following 5 days of
IL-22 injections (Figure 5d). This is not surprising, given that
IL-22-mediated keratinocyte hyperproliferation in vivo takes
longer to occur (approximately 2 weeks) (Ma et al., 2008).
Our results do not exclude other chemokine–chemokine
receptor interactions in mediating Th17 cell chemotaxis (for
example, involvement of CCR4). In fact, prominent redun-
dancy in leukocyte-trafficking pathways has been well
documented. Thus, elucidation of additional mechanisms
by which Th17 cells may enter the skin requires further study.
Our findings suggest a novel paradigm for human Th17
disease. Human Th17 cells are able to maintain their own
presence in peripheral inflamed tissue by secreting cytokines
that stimulate epithelial cells to produce the chemokine
CCL20, which in turn induces chemotaxis of additional Th17
cells. This biologic paradigm fits with clinical disease features
of psoriasis. Clinical features of skin affected by psoriasis (for
example, erythema, induration, and scaling) are remarkably
stable when untreated. Persistent presence of Th17 cells
within the dermis driven by a continual chemotactic gradient
coming from epidermal KC would manifest as phenotypically
stable skin. Breaking this cycle would require the death of
Th17 cells. The experimental biologic agents ustekinumab
and ABT 874, which are monoclonal antibodies directed
against the p40 subunit of IL-23, lead to dramatic clinical
improvement in psoriasis (Krueger et al., 2007; Kimball et al.,
2008; Leonardi et al., 2008; Papp et al., 2008). We postulate
that these agents are clinically effective in psoriasis because
they block IL-23, the cytokine signal needed by Th17 cells to
survive. Death of Th17 cells would stop Th17 cytokine
production, and thus break the chemotactic gradient present
in psoriasis. Future mechanism of action studies using
psoriatic skin obtained from individuals receiving anti-p40
monoclonal antibody therapy are necessary to test this
hypothesis. Our findings also suggest the possible therapeutic
use of agents designed to block chemokine–chemokine
receptor interactions in patients with psoriasis.
MATERIALS AND METHODS
IHC
The OHSU Institutional Review Board approved all of the described
studies, and the study was conducted according to the Declaration
of Helsinki Principles. For archival tissue, written informed consent
was waived as the tissue specimens were anonymized. Formalin-
fixed, paraffin-embedded lesional skin obtained from seven indivi-
duals with psoriasis and three healthy individuals were retrieved
from the OHSU dermatopathology archives maintained by Dr
Clifton White. Sections were de-paraffinized and hydrated through
heating and washing sections in a graded alcohol series. The sections
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Figure 3. IL-17A, IL-22, and TNF-a increase CCL20 protein expression by normal human KC in a dose- and time-dependent manner in vitro. Cells were treated
with the indicated concentrations of (a) IL-17A, (b) IL-22, or (c) TNF-a for 24 hours. Cells were treated with the optimal cytokine concentrations of (d) IL-17A, (e)
IL-22, or (f) TNF-a for 6, 24, or 48 hours. Cell-free supernatants were harvested and CCL20 protein levels were quantified by ELISA for all experiments. All
experiments were performed in triplicate at least three separate times and the average protein levels and SD are reported. Significant differences were detected
using the Mann–Whitney unpaired two-tailed t-test (*Indicates significance, Po0.05).
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were incubated in antigen-unmasking solution (Vector Laboratories,
Burlingame, CA) at 95 1C for 20minutes, and then exposed to either
goat anti-human IL-17A polyclonal Abs (R&D Systems, Minneapolis,
MN) or rabbit anti-human CD3 (Thermo Fisher Scientific, Waltham,
MA) monoclonal Abs overnight at 4 1C. Samples were washed and
incubated for 1 hour with biotinylated anti-goat or anti-rabbit
secondary Abs (Vector Laboratories), followed by 1 hour incubation
with streptavidin-conjugated horseradish peroxidase (Vectastain
Elite ABC kit, Vector Laboratories), developed using Vector VIP
substrate kit for peroxidases (Vector Laboratories), and counter-
stained with hematoxylin (Vector Laboratories).
For fresh tissue, patients first gave their written informed consent.
Four-mm punch biopsies of lesional skin from six individuals with
psoriasis were obtained and frozen immediately in OCT compound.
Frozen sections were cut, fixed with methanol for 10minutes,
and then incubated with either rabbit anti-human IL-22 polyclonal
Abs (Capralogics, Hardwick, MA) or CD3 mAbs overnight at 4 1C.
Samples were washed and incubated for 1 hour with biotinylated
anti-rabbit secondary Abs (Vector Laboratories) and developed and
counter-stained as above.
Frozen mouse skin sections were cut and fixed in methanol for
10minutes and incubated overnight with rat anti-mouse CD3
monoclonal Abs (Biolegend, San Diego, CA). Sections were then
incubated for 1 hour with biotinylated goat anti-rat secondary Abs
(Jackson ImmunoResearch Laboratories, West Grove, PA), for
45minutes with streptavidin-conjugated horseradish peroxidase
(Vectastain Elite ABC kit, Vector Laboratories), and developed and
counter-stained as above.
All IHC images were captured using a microscope equipped with
Imagepro software. For each antibody, the number of positive cells
was counted in 10 separate high-powered ( 40) fields and then
divided by 10 to obtain the average number of positive cells per
high-powered field.
Normal human KC cultures
Primary normal human KC (Cascade Biologics, Portland, OR) were
cultured in Keratinocyte Growth Media containing bovine pituitary
extract, human epidermal growth factor, insulin, hydrocortisone,
gentamicin, and amphotericin B. Cytokine stimulation experiments
were initiated on 60% confluent KC cultured between passages 2–5 in
6cm plastic dishes at 37 1C in the presence of 0.05% heat-inactivated
bovine serum albumin and in the absence of hydrocortisone. KC were
cultured either alone or with one of the following cytokines: 1, 10,
100, or 1,000ngml1 of IL-17A; 0.1, 1, 10, or 100ngml1 of IL-22,
TNF-a, or IFN-g; or 0.002, 0.02, 0.2, or 2ngml1 of TGF-b1 (R&D
Systems). At indicated time points following cytokine exposure,
conditioned culture media and cells were collected for CCL20 protein
and mRNA quantification, respectively.
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Figure 4. IL-17A, IL-22, and TNF-a increase CCL20 mRNA and protein expression by RHE in a dose- and time-dependent manner. Stratified KC in RHE were
treated with the indicated concentrations of (a) IL-17A, (b) IL-22, or (c) TNF-a for 6 or 24 hours. Total RNA was harvested and CCL20 transcripts were quantified
by real-time RT-PCR analyses. RHE were treated with the optimal cytokine concentrations of (d) IL-17A, (e) IL-22, or (f) TNF-a for 6 or 24 hours. Cell-free
supernatants were harvested and CCL20 protein levels were quantified by ELISA. All experiments were performed in triplicate at least three separate times and
the average protein levels and SD are reported. Significant differences were detected using the Mann–Whitney unpaired two-tailed t-test (*Indicates significance,
Po0.05).
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RHE cultures
HEKn-E6/E7 cells were established and propagated as described
(Iordanov et al., 2002, 2005). HEKn-E6/E7 were propagated in
EpiLife basal KC medium (BKM) (Cascade Biologics) supplemented
with a semi-defined human keratinocyte growth supplement (HKGS)
(Cascade Biologics), which included bovine pituitary extract, bovine
insulin, hydrocortisone, bovine transferrin, and human epidermal
growth factor. RHE were established as described (Poumay and
Coquette, 2007). Briefly, HEKn-E6/E7 cells were plated at
5 105cells per ml on 0.4 mm, 12mm-diameter polycarbonate
membranes (Millipore, Billerica, MA) and allowed to reach
confluence in BKMþHKGS. Cells were then exposed to the
air–liquid interface by removing the medium above the confluent
monolayer. Simultaneously, the cells were exposed from underneath
the monolayer to a differentiation medium (BKMþHKGSF supple-
mented with 1.5mM CaCl2, 50mgml
1 ascorbic acid, and 10ngml1
rhKGF (Peprotech, Rocky Hill, NJ)). The differentiation medium was
changed every 48 hours for 14 days. RHE cultures were treated with
10 or 100 ngml1 of IL-17A, IL-22, or TNF-a, and incubated at
37 1C. At indicated time points following cytokine exposure,
conditioned culture media and cells were collected for CCL20
protein and mRNA quantification, respectively.
Real-time RT-PCR
Cells from normal human KC monolayer and RHE cultures were
lysed directly in TRIzol, whereas mouse ear tissue was minced first
and then placed in TRIzol and total RNA was extracted according to
the manufacturer’s instructions (Invitrogen, Carlsbad, CA). Integrity
of RNA was determined by the appearance of distinct 28S and 18S
rRNA bands when analyzed by electrophoresis on 1% agarose gels.
The iScript kit (Bio-Rad, Hercules, CA) was employed for cDNA
synthesis and resulting cDNA was analyzed to determine CCL20
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Figure 5. CCL20 and CCR6 upregulation and T-cell infiltration in murine skin injected with Th17 cytokines. (a–c) Balb/c mouse ears were injected with 500 ng
of IL-17A, IL-22, TNF-a, or PBS daily for 5 days. (a and c) CCL20 and CCR6 mRNA expression levels in injected ears were determined by real-time RT-PCR.
Significant differences were detected using the Mann–Whitney unpaired two-tailed t-test (*Indicates significance, Po0.05). (b) CCL20 protein expression was
measured by ELISA. Significant differences were detected using the unpaired t-test with Welch’s correction (*Indicates significance, Po0.05). (a–c) Data from 10
mice in each treatment group are shown. (d) Representative histologic photos showing CD3 positive T cells in murine skin injected with Th17 cytokines.
Bar¼40 mm.
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mRNA levels relative to GAPDH mRNA levels. cDNA was amplified
using SYBR green (Bio-Rad) and the following primers: human
CCL20, forward TACTCCACCTCTGCGGCGAATCAGAA, and re-
verse GTGAAACCTCCAACCCCAGCAAGGTT; human GAPDH,
forward GAGTCAACGGATTTGGTCGT, and reverse TTGATTTTG
GAGGGATCTCG. Primers were annealed at 60 1C and amplified
using My IQ single color RT-PCR detection system (Bio-Rad) for a
total of 40 cycles.
ELISA
Secreted CCL20 protein levels in conditioned human KC culture
media were quantified using the Quantikine ELISA kit according to
the manufacturer’s protocol (R&D Systems). For the murine studies,
total protein was extracted from ears by snap-freezing tissue in liquid
nitrogen, pulverizing tissue while immersed in liquid nitrogen, and
subsequently re-suspending in cell extraction buffer (Invitrogen).
Samples underwent three freeze-thaw cycles and were centrifuged at
full speed for 15minutes to fractionate samples and remove protein.
Mouse CCL20 ELISA (R&D Systems) was performed according to the
manufacturer’s instructions using 150 mg total protein.
Animal studies
The Portland VA Medical Center Institutional Animal Care and Use
Committee approved all of the described studies using mice. Wild
type Balb/c mice were injected in each ear with either 500 ng of IL-
17A, IL-22, or TNF-a in 25 ml of PBS/0.1% of BSA, or with 25ml of
PBS/0.1% BSA alone. Ten animals per cytokine treatment group
were injected daily for 5 days. All animals were killed at day 5 and
mRNA was extracted from ears using a standard Trizol protocol,
followed by further purification using an RNeasy kit (Qiagen,
Valencia, CA). cDNA was synthesized using an iScript cDNA
synthesis kit (Bio-Rad) and amplified using Taqman primers and
fluorescent probes for GAPDH, CCL20, and CCR6 using My IQ
single color RT-PCR detection system for a total of 40 cycles.
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